Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.004 uM | inhibitory activity of compound against Multidrug resistant HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
IC50 (functional) | = 0.004 uM | inhibitory activity of compound against Multidrug resistant HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
IC50 (functional) | = 0.1 uM | inhibitory activity of compound against Multidrug resistance HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
IC50 (functional) | = 0.1 uM | inhibitory activity of compound against Multidrug resistance HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
IC50 (functional) | = 20 uM | Intrinsic cytotoxic activity of the compound against Multidrug resistant HCT116/VM46 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 20 uM | Intrinsic cytotoxic activity of the compound against Multidrug resistant HCT116/VM46 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 30 uM | Intrinsic cytotoxic activity of the compound against wild type HCT116 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 30 uM | Intrinsic cytotoxic activity of the compound against wild type HCT116 cell line | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 15546712 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.